+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Company Analysis: BioMarin

The publisher explores BioMarin’s prescription pharmaceutical performance and outlook over 2019-29.


  • Overview - BioMarin’s ultra-rare diseases portfolio will maintain its solid growth and attractive orphan drug potential.
  • Key themes - [1] BioMarin is set to double its pharmaceutical revenue over the forecast period [2] Approvals of Roctavian (valoctocogene roxaparvovec) and vosoritide are critical to long-term growth.

Model updates (6 November 2020)

  • Palynziq forecast adjusted lower
  • Vimizim forecast adjusted lower
  • Roctavian forecast adjusted lower due to CRL.

Model updates (5 August 2020)

  • Aldurazyme forecast adjusted higher
  • Brineura forecast adjusted lower
  • Palynziq forecast adjusted lower
  • Kuvan forecast adjusted higher due to price increases in the US and product mix.

Model updates (29 April 2020)

  • Vimizim forecast lowered due to impact from COVID-19
  • Palynziq forecast lowered due to impact from COVID-19
  • Valoctocogene roxaparvovec name changed to Roctavian.

Model updates (26 February 2020)

  • Palynziq forecast adjusted higher due to continued growth due to switching from Kuvan
  • Firdapse forecast removed due to sale to SERB.

Table of Contents

Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison

Recent Earnings Review
  • Earnings Overview
  • Pharma Insights Analysis

Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis

Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights

Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug